research Diclofenac/imiquimod
Some elderly men had healing problems after using imiquimod and diclofenac for skin conditions on their scalps.
Search
for
Sort by
Research
30 / 1000+ results 
research Medications
Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
research Persistierende Wundheilungsstörungen nach Lokaltherapie von Feldkanzerisierung des Capillitiums mit Imiquimod oder Diclofenac
Older men with scalp wounds had long-term healing problems after using imiquimod or diclofenac for skin cancer prevention.
research Cystitis Due to Cytoxan: Case Report
A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
research Editorial Note on Next-Generation Therapies and Advance Acne Treatment
New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.
research An Underrecognized Adverse Effect of Azithromycin
Azithromycin can rarely cause a severe drop in white blood cells.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Advances in histamine-mediated allergy management: Expanding perspectives on cetirizine’s therapeutic, safety, and toxicological implications
Cetirizine is effective and safe for treating various allergies, with personalized dosing improving its use.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.
research Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices
Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
Clascoterone 1% cream is a promising new treatment for acne.
research Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases
Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.
research Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research NEW PROPRIETARY BRANDS: Cefaclor monohydrate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade — a single-center retrospective study
Cyclophosphamide often causes gastrointestinal issues, hair loss, and low blood cell counts in Chinese patients with autoimmune diseases.
research The Impact of Lactobacillus-Rich Probiotic Nutrition on the Pharmacological Efficacy of Clotrimazole Delivered via Mucoadhesive Thermosensitive Hydrogels in Human Subjects with Recurrent Candidiasis
Combining probiotics, clotrimazole gel, and laser therapy improves treatment for recurrent yeast infections.
research OA08 Ocrelizumab in pregnancy in a patient with juvenile onset systemic lupus erythematosus
Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Combination of Low-Dose Isotretinoin and Pulsed Oral Azithromycin in the Management of Moderate to Severe Acne
Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Application of Acyzol in the Context of Zinc Deficiency and Perspectives
Acyzol could help treat conditions caused by zinc deficiency.
research [Lupus cystitis and peritonitis successfully treated with intravenous cyclophosphamide pulse therapy: a case report].
Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.
research Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience
Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
research Evaluation of the Effectiveness of Ciprofloxacin in Comparison to Clindamycin Solutions on Acne Vulgaris
Ciprofloxacin is slightly more effective than Clindamycin for reducing acne.
research Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19
Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.